Clinical Trial: GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

Study Status: Terminated
Recruit Status: Terminated
Study Type: Observational

Official Title: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol

Brief Summary: This study will collect safety information on the use of GARDASIL™ in the Philippines.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Number of participants with adverse events following any dose of vaccine [ Time Frame: At least 30 days following any vaccine dose ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: May 16, 2011
Date Started: February 2008
Date Completion:
Last Updated: August 11, 2015
Last Verified: August 2015